ARCHIVES

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Supports Development Of Reinoids for Prevention; No Magic Bullet

May 6, 1977

Patient Harm—Including One Death—Cited As Faculty Challenges MD Anderson Leadership

September 20, 2013

Cooney to Oversee University of Michigan Clinical Operations

February 7, 2013

Beth Israel Suspends Enrollment In Trials Following An Audit

October 22, 2010

Consensus Conference Suggest Research Required For Advances In Pain Control

May 30, 1986

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001